Latest Breaking News On - Warschaw robertson law families chair - Page 1 : comparemela.com

Dr Freedland on the FDA Approval of Enzalutamide in nmCSPC

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Stephenj freedlandResearch in cancerPrevention programDepartment of urologySamuel oschin comprehensive cancer instituteWarschaw robertson law families chairProstate cancerIntegrated researchCancer geneticsCedars sinaiNonmetastatic castration sensitive prostate cancer

Pfizer, Astellas Pharma Xtandi combo therapy cuts risk of metastasis, death by 58 percent in prostate cancer

XTANDI (enzalutamide) is an androgen receptor signaling inhibitor.

United statesStephenj freedlandEuropean unionCarolina urologic research centerResearch in cancerDrug administrationNeal shoreMedical officerSurgical oncologyPrimary investigatorIntegrated researchWarschaw robertson law families chairProstate cancerCedars sinai cancerCo principal investigatorPfizer news

Enzalutamide Combination, Monotherapy Reduced the Risk of Metastasis or Death in High-Risk Patients With Prostate Cancer

Immature data suggest enzalutamide combination improves overall survival in patients with high-risk biochemical recurrence.

United statesAstellas pharmaEnzalutamide xtandiStephenj freedlandCarolina urologic research centerResearch in cancerAmerican urological association annual meetingLupron depotUrological association annualNeal shoreSurgical oncologyIntegrated researchWarschaw robertson law families chairProstate cancerCedars sinai cancer

Enzalutamide & Leuprolide Cut Metastasis Risk by 58% in Prostate Cancer

Enzalutamide & Leuprolide Cut Metastasis Risk by 58% in Prostate Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesStephenj freedlandNaoki okamuraResearch in cancerPfizer incAmerican urological association annual meetingCarolina urologic research centerAstellas pharma incDrug administrationAmerican urological association annualAstellas pharmaHazard ratioConfidence intervalNeal shoreMedical officerSurgical oncology

Enzalutamide With or Without Leuprolide Offers MFS Benefit Vs Leuprolide Alone in nmHSPC With High-risk BCR

Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

United statesMyrtle beachSouth carolinaLos angelesStephenj freedlandAlmeida luzCarolina urologic research centerResearch in cancerGenesiscare united statesIntegrated researchWarschaw robertson law families chairProstate cancerCedars sinai cancerLeuprolide reducedNon metastatic hormone sensitive prostate cancerAmerican urological association annual meeting